|Day Low/High||209.34 / 215.50|
|52 Wk Low/High||197.47 / 306.08|
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
The short-term charts of VRTX suggest that this stock can see further sideways to lower price action in the weeks ahead.
Investors should continue to hold their positions on VRTX.
There was a mild increase in trading volume at the New York Stock Exchange, but it was a rotational shift.
Oil isn't really worthless and Amazon isn't the only retailer that will survive, but we are in a mixed up market thanks to Covid-19.
The pace of the rally in the drugmaker's shares is slowing, which is one reason to keep an eye on its stock.
VRTX is poised for further upside price gains.
The indices are within striking distance of the July highs after moving into position for a possible strong finish to the year.
Straying from these names could land you in quicksand as the 4th quarter begins.
It is all about perception, and here are strong names to pick up on market weakness.
The potential of these setups on the weekly chart is rather good.
After pharmaceutical company breaks out, charts suggest now is the time to go back in.
Look no further than the top 10 winners in the S&P 500 and you will see just what I mean.
Of stocks seeing the biggest gains since the presidential election, only a few owe their success to Trump.
Trade from the long side, but have a sell stop below $149 in case of a reversal.
Let's examine VRTX's sharp decline today.
Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday
The Nasdaq and S&P 500 ended at records for the second day in a row.
It's a wonder to me how split this market really is.
"The rally in the face of today's data (detailed by Peter Boockvar in the previous post) tells me how much machines and algos dominate trading: a mild winter goosed construction jobs service job data is so-so ISM services has just given back the ent...
It's pretty normal to have profit-taking after such a strong first quarter.
A rally in crude oil gave rise to the energy sector in a mixed day of trading.
Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.